Italy-based Stevanato Group, a producer of glass primary packaging and provider of integrated capabilities for drug delivery systems, and Bexson Biomedical Inc., a research stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, have signed an agreement. The collaboration will focus on developing a customized version of the SG EZ-be Pod, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.    The two c...